MolNFT v1 · #72942 · protein
Halogenase domain from cura module with fe, chloride, and alpha- ketoglutarate
3NNF: “Halogenase domain from cura module with fe, chloride, and alpha- ketoglutarate”. X-ray diffraction, 3 ligands (AKG, FE, CL), 3 pockets (best druggability 0.73). MolNFT v1 #72942 on GenesisL1: 3D structure, binding sites and pockets…
- PDB
- 3NNF
- Type
- protein
- Length
- 318 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Cura
- UniProt
- Q6DNF2
- Ligands
- AKG, FE, CL
- Pockets
- 3 · best druggability 0.73
Structure
x-ray diffraction · 1 distinct chain · 42% helix, 20% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Cura | protein | 318 | 42% helix, 20% strand | Q6DNF2 |
Ligands and binding sites
- AKG · 2-oxoglutaric acid · ligand · chains A
- FE · Fe (III) ion · metal · chains A
- CL · Chloride ion · ion · chains A
- FMT · Formic acid · additive · 6 copies · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
3 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 150 | 0.73 | 0.91 | 44 | FE, FMT, AKG |
| 2 | 147 | 0.55 | 0.81 | 30 | FMT |
| 3 | 76 | 0.37 | 0.77 | 15 | empty |
Compared structures
- 3NNF · Halogenase domain from CurA module with Fe, chloride, and alpha-ketoglutarate · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt Q6DNF2
- Elsewhere: RCSB PDB 3NNF · PDBe 3NNF · UniProt Q6DNF2
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.